Work

HCM Risk-SCD score and its relation with functional status and comorbidities in HCM patients

Year: 2026
Type: article
Study design: Observational Study
Abstract: Introduction Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder associated with heart failure, arrhythmias, and an increased risk of sudden cardiac death (SCD). Functional status and the HCM Risk-SCD score are key parameters guiding management. This study assessed the relationship between functional status, comorbidity burden, and the HCM Risk-SCD score in patients with HCM. Material and methods This retrospective single-cohort study included 56 patients with HCM. The HCM Risk-SCD score was calculated according to the 2023 ESC guidelines. Patients were stratified by heart failure symptoms into asymptomatic (NYHA I) and symptomatic (NYHA II–III) groups, and by comorbidity burden into low (0–1) and high (≥2) groups. Assessed comorbidities included systemic hypertension, hyperlipidemia, coronary artery disease, chronic kidney disease, COPD, and type 2 diabetes. Results The median HCM Risk-SCD score was higher in asymptomatic than symptomatic patients (3.46% [IQR 2.38-4.44] vs. 2.07% [IQR 1.17-2.23]; p=0.005). No significant difference was observed between patients with low and high comorbidity burden (1.95% vs. 2.01%; p=0.765), and no correlation was found between the HCM Risk-SCD score and the number of comorbidities (rho=-0.07, p=0.607). Conclusions Asymptomatic patients with HCM had a higher estimated risk of SCD than symptomatic patients. The HCM Risk-SCD score appeared to be independent of comorbidity burden. This shows that HCM individuals with better clinical and functional status may be at higher risk of SCD.
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7233745309
FWCI:
Cites: 21
Cited by:
Related to: 10